
Verastem Publishes Phase 2 Results for Avutometinib Combo in Ovarian Cancer
Verastem Oncology Publishes Phase 2 RAMP 201 Results: Avutometinib + Defactinib in Recurrent LGSOC Primary analysis from the ENGOT‑OV60/GOG‑3052/RAMP 201 study reported in the Journal of Clinical Oncology, showing a 31% overall response rate in recurrent low‑grade serous ovarian cancer. Verastem…